Renato Chirivi

Renato Chirivi is co-founder of Citryll and previously CSO. He has been central, with CEO Helmuth van Es in bringing Citryll to its current clinical develpment status. He is the co-inventor of therapeutic anti-citrullinated protein antibodies (tACPA), antagonists of NET biology, and an expert on antibody discovery, engineering, production, and protein citrullination. He has numerous years of experience in cancer, neurobiology and molecular immunology which he gained at the Mario Negri Institute for Pharmacological Research in Italy, The Scripps research institute in California, USA, the Nijmegen Center for Molecular Life Sciences, and ModiQuest BV, the Netherlands. Renato is responsible for technology development, MoA programme of Citryll's NET antagonist, intellectual property and specific therapeutic areas.